Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: Adequate pain management is an essential key to success in endodontics. The present study aimed to evaluate the postoperative pain levels and analgesic intake on preemptive versus preventive oral administration of ibuprofen in single visit root canal treatment.

Methods: A total of 100 participants presented with symptomatic irreversible pulpitis and with severe baseline pain scores were selected for the study. The participants were randomly allocated into two groups as follows: Group I: preemptive group (n=50), Group II: preventive group (n=50). Participants in group I were administered preoperatively with 600 mg of ibuprofen tablet 1 hour before the procedure, whereas in group II, participants were administered only with a placebo preoperatively. The treatment was finished in a single visit, and 200 mg ibuprofen tablet was administered every eight hours in both groups. The participants were asked to take tablets only when required and evaluated for pain scores and analgesic intake at 6, 24, 48, 72 hour intervals.

Results: There was a statistically significant decrease (P<0.05) in both the pain levels and tablet intake in the preemptive group compared to the preventive group at 6, 24, 48 and 72 hours. Preemptive group was beneficial in reducing postoperative pain scores and analgesic intake at all time intervals.

Conclusion: Preemptive analgesic administration seems beneficial in reducing postoperative pain levels and analgesic intake in single visit root canal treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285989PMC
http://dx.doi.org/10.14744/eej.2021.49469DOI Listing

Publication Analysis

Top Keywords

single visit
12
ibuprofen single
8
visit root
8
root canal
8
analgesic intake
8
pain scores
8
group n=50
8
ibuprofen tablet
8
group
6
participants
5

Similar Publications

Targeted intraoperative radiotherapy (IORT) delivers a single dose of radiation to a fresh tumour bed immediately after lumpectomy, commonly used to treat early breast cancer (EBC). It is delivered during the same sitting, with improved patient compliance and better sparing of adjacent healthy tissue, compared to conventional adjuvant radiotherapy to the whole breast. The recently published 12-year results (median follow up of 8.

View Article and Find Full Text PDF

Purpose: Cerebral Visual Impairment (CVI) is the leading cause of paediatric visual impairment in developed countries. Earlier diagnosis provides access to early intervention, which may improve visual function, functional vision and developmental outcomes. The purpose of this study was to determine the age and timing of CVI diagnosis and the severity of CVI.

View Article and Find Full Text PDF

Background: The prognosis of small-cell lung cancer (SCLC) remains poor, particularly in patients with extensive-stage SCLC. The IMpower133 and CASPIAN trials revealed the efficacy of immune checkpoint inhibitors (ICIs) in extensive-stage SCLC patients with good performance status (PS). The aim of this study was to investigate the efficacy of ICIs in patients with poor PS.

View Article and Find Full Text PDF

Aim    Search for subclinical manifestations of cardiotoxicity in cancer patients at high and very high risk of cardiotoxicity and evaluation of the effectiveness of drug primary prevention during the antitumor treatment. Material and methods    The study included 150 cancer patients with a high and very high Mayo Clinic (USA) Cardiotoxicity Risk Score. The main group consisted of 84 patients at high and very high risk of cardiotoxicity who were prescribed cardioprotective therapy, including a fixed combination of the angiotensin-converting enzyme inhibitor (ACEI) perindopril and the beta-blocker bisoprolol with trimetazidine.

View Article and Find Full Text PDF

Purpose This study aims to compare the initial three-month outcomes of a single-center experience with small incision lenticule extraction (SMILE) for correction of myopia and myopic astigmatism using the VisuMax 500 (Carl Zeiss Meditec, Jena, Germany) versus the VisuMax 800 (SMILE Pro®; Carl Zeiss Meditec, Jena, Germany). This experience is compared to the US Food and Drug Administration approval studies and published literature. Patients and methods The initial 45 eyes (23 patients) that underwent SMILE with the VisuMax 500 in 2018 were compared with the initial 42 eyes (21 patients) that underwent SMILE Pro® with the VisuMax 800 in 2024.

View Article and Find Full Text PDF